Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved both VYNDAQEL® (tafamidis meglumine) and VYNDAMAX
Source: www.businesswire.com
The U.S. Food and Drug Administration (FDA) has given its approval to Pfizer’s drugs VYNDAQEL (tafamidis meglumine) and VYNDAMAX (tafamidis). These drugs are used for the treatment of cardiomyopathy of wild-type, or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality and cardiovascular-related hospitalization. Both drugs come in oral formulations of the first-in-class transthyretin stabilizer tafamidis, and are the first and only medicines approved by the FDA to treat ATTR-CM.
